Absorption of clonidine from a halved transdermal system - A pilot study

Journal of Pharmacy Technology

Volumn 17, Issue 3, 2001, Pages 84-89

  Wong, Nina N ^a   Chen, Julie L ^a   Luks Golger, Denise ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLONIDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; NORMAL HUMAN;

EID: 0035017858     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250101700302     Document Type: Article

References (37)

1. Package insert. Catapres-TTS (clonidine). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., October 1996.
2. Package insert. Duradon (clonidine hydrochloride injection). Deerfield, IL: Fujisawa USA, Inc., September 1996.
3. Hunt RD, Capper L, O'Connell P. Clonidine in child and adolescent psychiatry. J Child Adolesc Psychopharmacol 1990;1:87-102.
4. Wilens TE, Biederman J, Spencer T. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1994;33:424-6.
5. Kemph JP, DeVane CL, Levin GM, Jarecke R, Miller RL Treatment of aggressive children with clonidine: results of an open pilot study. J Am Acad Child Adolesc Psychiatry 1993;32:577-81.
6. Steingard R, Biederman J, Spencer T, Wilens T, Gonzalez A. Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 1993;32:350-3.
7. Polak L, Molcan J. Clonidine in hyperkinetic children. Act Nerv Super (Praha) 1990;32:66-7.
8. McKeith IG, Williams A, Nicol AR. Clonidine in Tourette syndrome (letter). Lancet 1981;1:270-1.
9. Cohen DJ, Young JG, Nathanson JA, Shaywitz BA. Clonidine in Tourette's syndrome. Lancet 1979;2:551-3.
10. Giannini AJ, Sullivan B, Sarachene J, Loiselle RH. Clonidine in the treatment of premenstrual syndrome: a subgroup study. J Clin Psychiatry 1988;49:62-3.
11. Nilsson LC, Eriksson E, Carlsson M, Soderpalm B. Clonidine for relief of premenstrual syndrome (letter). Lancet 1985;2:549-50.
12. Kinzie JD, Sack RL, Riley CM. The polysomnographic effects of clonidine on sleep disorders in posttraumatic stress disorder: a pilot study with Cambodian patients. J Nerv Ment Dis 1994;182:585-7.
13. Charney DS, Heninger GR. Abnormal regulation of noradrenergic function in panic disorders: effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1986,43:1042-54.
14. Gourlay SG, Benowitz NL. Is clonidine an effective smoking cessation therapy? Drugs 1995;50:197-207.
15. Gourlay S, Forbes A, Marriner T, Kutin J, McNeil J. A placebo-controlled study of three clonidine doses for smoking cessation. Clin Pharmacol Ther 1994;55:64-9.
16. Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 1987;13:1-17.
17. Wilson RS, DiGeorge WS. Methadone combined with clonidine versus clonidine alone in opiate detoxification. J Subst Abuse Treat 1993;10:529-35.
18. Charney DS, Heninger GR, Kleber HD. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am J Psychiatry 1986;143:831-7.
19. Adinoff B. Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: preliminary findings. Alcohol Clin Exp Res 1994;18:873-8.
20. Baumgartner GR, Rowen RC. Transdermal clonidine versus chlordiazepoxide in alcohol withdrawal: a randomized, controlled clinical trial. South Med J 1991;84:312-21.
21. Manhem P, Nilsson LH, Moberg AL, Wadstein J, Hokfelt B. Alcohol withdrawal: effects of clonidine treatment on sympathetic activity, the renin-aldosterone system, and clinical symptoms. Alcohol Clin Exp Res 1985;9:238-43.
22. Wong V, Sobala G, Losowsky M. A case of narcotic bowel syndrome successfully treated with clonidine. Postgrad Med J 1994; 70:138-40.
23. Goyagi T, Nishikawa T. Oral clonidine premedication enhances the quality of postoperative analgesia by intrathecal morphine. Anesth Analg 1996;82:1192-6.
24. Lowenthal DT, Matzek KM, MacGregor TR. Clinical pharmacokinetics of clonidine. Clin Pharmacokinet 1988;14:287-310.
25. McEvoy GK, ed. American hospital formulary service drug information 98. Bethesda, MD: American Society of Health-System Phamacists, 1998:1471-7.
26. Chandraskaran SK, Darada S, Michaels AS, Cleary GW. US Patent 4,201,211; assigned to Alza Corporation and Boehringer Ingelheim GmbH, Germany, May 6, 1980.
27. Shaw JE, Enscore D, Chu L. Clonidine rate-controlled system: technology and kinetics. In: Weber MA, Mathias CJ, eds. Mild hypertension - current controversies and new approaches. Steinkopff Verlag Darmstadt, 1984:134-42.
28. Arndts D, Arndts K. Pharmacokinetics and pharmacodynamics of transdermally administered clonidine. Eur J Clin Pharmacol 1984;26:79-85.
29. MacGregor TR, Matzek KM, Keirns JJ, van Wayjen RGA, van den Ende A, van Tol RGL. Pharmacokinetics of transdermally delivered clonidine. Clin Pharmacol Ther 1985;38:278-84.
30. Toon S, Hopkins KJ, Aarons L, Rowland M. Rate and extent of absorption of clonidine from a transdermal therapeutic system. J Pharm Pharmacol 1989;41:17-21.
31. Fujimura A, Sasaki M, Harada K, Kumagai Y, Ohashi K, Ebihara A. Influences of bathing and hot weather on the pharmacokinetics of a new transdermal clonidine, M-5041T. J Clin Pharmacol 1996;36:892-6.
32. Lee HA, Anderson PO. Giving partial doses of transdermal patches. Am J Health Syst Pharm 1997;54:1759-60.
33. Stolley PD, Strom BL. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 1986;39:489-90.
34. Arndt KA, Bowers KE, Chuttani AR. Manual of dermatologic therapeutics: with essentials of diagnosis. 5th ed. Boston: Little, Brown and Co., 1995.
35. Maibach HI, Wester RC. Issues in measuring percutaneous absorption of topical corticosteroids. Int J Dermatol 1992;31(suppl 1):21-5.
36. West DP, Maddux SV. Topical anti-infective products. In: Covington TR, ed. Handbook of nonprescription drugs. 10th ed. Washington, DC: American Pharmaceutical Association, 1993:495-6.
37. Guy RH, Hadgraft J. Structure-activity correlations in percutaneous absorption. In: Bronaugh RL, Maibach HI, eds. Percutaneous absorption. 2nd ed. New York: Marcel Dekker, 1989:13-26.